Compare Amylx Pharmaceuticals Inc (AMLX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Tripadvisor Inc Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.63B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| AMLX | TRIP | |
|---|---|---|
Market Cap | $1.98B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $19.14 |
52-Week Low | $7.64 | $9.24 |
Enterprise Value | $1.70B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
TRIP trades at $13.98, up 4.88% today, near the consensus price target of $13.87. The stock shows a bullish technical signal with support at $13 and resistance at $14. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company's $700 million sale of TheFork to American Express in June 2026 provides a cash infusion but highlights strategic refocusing amid competitive pressures.
The outlook is cautious; while the sale simplifies the business and boosts liquidity, core revenue growth remains modest and net margins are thin at 0.99%. Analyst sentiment is neutral with 60.72% hold ratings. Key risks include execution on the narrowed strategy and travel industry volatility. The stock appears fairly valued with a P/E of 127.09 reflecting low earnings, but the P/S of 0.93 suggests potential if top-line expansion accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
